Free Trial
NASDAQ:NEO

NeoGenomics 4/29/2025 Earnings Report

NeoGenomics logo
$7.70 +0.44 (+6.06%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$7.64 -0.06 (-0.78%)
As of 05/2/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeoGenomics EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.02
Beat/Miss
Missed by -$0.06
One Year Ago EPS
-$0.02

NeoGenomics Revenue Results

Actual Revenue
$168.04 million
Expected Revenue
$171.38 million
Beat/Miss
Missed by -$3.34 million
YoY Revenue Growth
+7.60%

NeoGenomics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NeoGenomics Earnings Headlines

NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript
NeoGenomics Pays Off 1.25% Convertible Senior Notes
Is he more powerful than Trump?
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
NeoGenomics (NASDAQ:NEO) Shares Gap Down on Analyst Downgrade
See More NeoGenomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeoGenomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeoGenomics and other key companies, straight to your email.

About NeoGenomics

NeoGenomics (NASDAQ:NEO) operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

View NeoGenomics Profile

More Earnings Resources from MarketBeat